Prolonged Protection From Bone Disease in Multiple Myeloma
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
Main hypothesis: Patients who continue zoledronic acid after year 2 have longer time until
progression in bone disease compared to patients who stop treatment after two years?
Secondary hypothesis: Serum will bone markers increase prior to progression in bone disease
in the individual patient?
Secondary hypothesis: Low-dose CT will detect more cases of osteolytic bone disease in
Multiple Myeloma compared to conventional radiography